semaglutide and heart disease GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Semaglutide Cuts Heart Risk Beyond

Grass Fed

9 The consensus statement from the American Association of Clinical Endocrinologists supports the use of GLP-1 RAs as first-line therapy in managing hyperglycaemia in T2D patients with established (or at high risk of) atherosclerotic CVD, as well as in those with chronic kidney disease or a history of stroke or transient ischaemic attack, while recommending the administration of sodiumglucose cotransporter 2 inhibitors to HF patients

The medication slows her digestion to the point where she feels perpetually full, making it hard to consume enough food throughout the day

Endocrine Rev 41(1):121

This is its primary mechanism for weight loss